## TrumpRx Anchor Companies Spent $130M Lobbying as Drug Pricing Plan Took Shape — Nearly 23% Surge Outpacing Industry
The 17 pharmaceutical companies anchoring the Trump administration's new prescription drug-pricing program — TrumpRx — collectively poured more than $130 million into federal lobbying in 2025, a spending surge that outpaced the broader industry by nearly 23% as the plan was being shaped behind closed doors, according to OpenSecrets data.

These companies represented more than a quarter of the record $457.3 million spent on lobbying across all sectors during the period in question. The concentration of influence among this relatively small group of pharmaceutical firms signals how major players moved aggressively to shape the contours of the pricing framework before it took formal shape. OpenSecrets, the nonprofit that tracks campaign financing and lobbying expenditures, documented the acceleration in spending as the administration developed its approach to prescription drug costs.

The lobbying surge raises questions about the degree to which industry priorities influenced the program's design. Companies with direct stakes in the outcome increased their Washington presence substantially during the very window when policy details were being negotiated. The scale of spending — roughly $130 million from a group of 17 companies — indicates coordinated, high-level engagement rather than reactive advocacy. Whether that influence translated into specific policy outcomes remains subject to analysis, but the timing and magnitude of the expenditures align with a period of active formulation for TrumpRx.
---
- **Source**: STAT News
- **Sector**: The Vault
- **Tags**: pharmaceutical lobbying, TrumpRx, drug pricing, OpenSecrets, federal lobbying
- **Credibility**: unverified
- **Published**: 2026-05-12 23:18:18
- **ID**: 82401
- **URL**: https://whisperx.ai/en/intel/82401